The endothelial cell inhibitor endostatin (22 kDa) is part of the carboxyl-terminal globular domain of collagen XVIII and shows a widespread tissue distribution. Immunohistology of adult mouse tissues demonstrated a preferred localization in many vessel walls and some other basement membrane zones. A strong immunogold staining was observed across elastic fibers in the multiple elastic membranes of aorta and other large arteries. Staining was less strong along sparse elastic fibers of veins and almost none was observed in the walls of arterioles and capillaries. Strong evidence was also obtained for some intracellular and basement membrane associations. Immunogold double staining of elastic fibers showed a close colocalization of endostatin with fibulin-2, fibulin-1, and nidogen-2, but not with perlecan. Reasonable amounts of endostatin could be extracted from aorta and skin by EDTA, followed by detergents, with aorta being the richest source of the inhibitor identified so far. Solubilizations with collagenase and elastase were ϳfivefold less efficient. Immunoblots of aortic extracts detected major endostatin components of 22-25 kDa whereas skin extracts also contained some larger components. Solid-phase assays demonstrated distinct binding of recombinant mouse endostatin to the fibulins and nidogen-2, consistent with their tissue colocalization. Together, the data indicate several different ways for endostatin to be associated with the extracellular matrix, and its release may determine biological activation. This also defines a novel function for some elastic tissues.-Miosge, N., Sasaki, T., Timpl, R. Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls. FASEB J. 13, 1743-1750 (1999) 
Angiogenesis is a process that is crucial during embryonic development and all other phases of tissue growth and repair; it is controlled by many stimulatory and inhibitory proteins, which in most cases interact through endothelial cell receptors (1-3). Perturbations of this balanced control seem to be associated with several pathological conditions that are not yet well defined at the molecular level. It would seem, however, that prevention of endogenous inhibition of angiogenesis is essential for tumor growth (4, 5) . A few angiogenesis inhibitors have in fact been shown to have a strong therapeutic potential in experimental tumor models (6, 7) . These endogenous inhibitors are a diverse group of proteins, including the chemokine platelet factor 4 (8) , prolactin (9) , and the angiostatin part of plasminogen (10) , which require proteolytic activation. Other putative inhibitors are typical extracellular matrix proteins and include fibronectin (11) , thrombospondin-1 (12, 13) , SPARC/BM-40/osteonectin (14) , and the collagen XVIII-derived endostatin (15) . Again, proteolysis may be required to generate an active inhibitory structure or for release in a soluble endocrine form. Yet the diverse structures of these inhibitors indicate that they are involved in different interactions, and their release and role in homeostatic control are still not well defined.
The endostatin inhibitor (180 residues) is part of the larger carboxyl-terminal globular domain NC1 (315 residues) of collagen XVIII (16, 17) and was originally isolated as an inhibitor of endothelial cell proliferation from hemangioendothelioma medium (15) . Recombinant endostatin from bacteria was largely insoluble, but shown to efficiently arrest tumor growth in vivo (7, 15) . A highly soluble recombinant mouse endostatin and the NC1 domain were obtained from mammalian cells; endostatin was shown by X-ray crystallography to be folded into a compact globular structure with some relationship to C-type lectins (18) . Antibodies raised against endostatin demonstrated its presence in serum, urine, and a large variety of tissues (19) . The tissue forms were mainly related in size to NC1, whereas the circulating form corresponded more closely to endostatin. Immunohistology of embryonic tissues demonstrated a strong reaction for endostatin in many, but not all, blood vessels and some other basement membrane zones. Further data showed similar in vitro binding properties of NC1 and endostatin for the microfibrillar fibulins, but higher affinities of NC1 for other extracellular ligands. This led us to speculate that after the initial proteolytic release of the procollagen-like NC1 domain, additional protease processing in a hinge region is required to produce an endocrine form of endostatin similar to that found in the circulation (19) .
To examine further the features of endostatin related to homeostasis, we have now used immunoelectron microscopy and found a strong association with elastic fibers of arteries. In aorta and skin, the size corresponded to that of circulating endostatin. There was also a distinct colocalization of endostatin with fibulin-1, fibulin-2, and nidogen-2, which correlated with in vitro binding of endostatin to these proteins. This indicates that large vessels represent a rich reservoir of endostatin whose role remains to be identified.
MATERIALS AND METHODS

Sources of proteins and antibodies
Mouse endostatin and NC1 domain (19) , mouse fibulin-1C (20) and fibulin-2 (21), and human nidogen-2 (22) were obtained as recombinant products from transfected mammalian cells. Recombinant human tropoelastin (rTE⌬26) from bacteria and a corresponding rabbit antiserum (23, 24) were kindly supplied by J. Rosenbloom. Perlecan was purified from a mouse tumor (25) . Affinity-purified rabbit antibodies against endostatin (19) , fibulin-1 (20) , fibulin-2 (21), nidogen-2 (22) , and perlecan fragment III-3 (26) were described previously. A rat monoclonal antibody against mouse endostatin was obtained by a lymph node injection protocol (27) in collaboration with Y. Ninomiya and colleagues (unpublished results).
Protein ligand and immunological binding assays
Solid-phase binding assays to plastic-immobilized recombinant mouse endostatin and affinity chromatography on a 1 ml heparin column have been described (19) . Immunoblotting of reduced tissue extracts was performed with affinity-purified antibodies (28) . A radioimmune inhibition assay specific for mouse endostatin was calibrated with recombinant endostatin for quantitative measurements (19) .
Tissue extractions and analysis
Freshly isolated aorta and skin from adult mice (0.22-0.26 g) were homogenized in 1.5 ml 0.05 M Tris-HCl, pH 7.4, 0.1 M NaCl (TBS) 2 and split into three aliquots. One 0.5 ml aliquot (procedure A) was extracted for 16 h at 4°C after addition of 10 mM EDTA and 1 mM protease inhibitor Pefabloc (Boehringer Mannheim, Mannheim, Germany). After centrifugation to obtain the EDTA buffer extracts, the residue was extracted with 0.5 ml of the same buffer containing in addition 1% Nonidet P-40, 0.5% deoxycholate, and 0.1% sodium dodecyl sulfate (28) for 4 h at 4°C (detergent extract). Another 0.5 ml aliquot of the TBS homogenate (procedure B) was supplemented with 0.25 mg pancreatic elastase (Serva, Heidelberg, Germany) and incubated for 16 h at 37°C in order to obtain an elastase digest. The residue was then incubated (4 h, 37°C) in 0.5 ml TBS containing 0.25 mg bacterial collagenase (Worthington, Freehold, N.J.). The reverse order of collagenase (16 h ) and elastase (4 h) was also used to obtain further extracts from an additional 0.5 ml aliquot (procedure C). In control experiments, recombinant endostatin was treated separately with elastase or collagenase (16 h, 37°C) at an enzyme substrate ratio of 1:30, which was approximately the same as the ratio of protease to total protein in the tissue digestions.
Aliquots of the tissue extracts were hydrolyzed with 6 M HCl (16 h, 110°C) and analyzed on a Biotronic LC 3000 amino acid analyzer to determine the total protein content. The collagen content was estimated from the 4-hydroxyproline values, assuming a content of 10 mol %, as is typical for the fibrillar collagens, which represent the majority of the collagens present in these tissues.
Immunohistological analyses
Affinity-purified rabbit antibodies against endostatin (10 g/ ml) were used on frozen tissue sections of adult mice and their binding was detected by fluorescence (Cy3)-conjugated goat anti-rabbit immunoglobulin G (IgG) following previous protocols (28) . Negative controls were performed with normal rabbit IgG (10 g/ml) and showed no substantial staining (not shown).
Tissue pieces (ϳ1 mm 2 ) of aorta, large vessels, kidney, liver, and skin of adult NMRI mice were fixed in 4% paraformaldehyde and 0.5% glutaraldehyde for 15 min, dehydrated, and embedded in the acrylic resin LR-Gold (London Resin Company, London, U.K.). Ultrathin sections were obtained with a Reichert ultramicrotome and collected on formvar coated nickel grids for immunoelectron microscopy as described previously (29) . Affinity-purified goat anti-rat IgG (0.7 mg/ml) and goat anti-rabbit IgG (1.0 mg/ml) were obtained from Medac (Hamburg, Germany) and used to coat either 8 or 16 nm colloidal gold particles, following standard protocols (30, 31) . Tissue sections were incubated at room temperature (15 min) with phosphate-buffered saline pH 7.4 (PBS), followed for 20 min with affinity-purified rabbit antibodies against endostatin (6 g/ml), fibulin-1 (6 g/ml), fibulin-2 (17 g/ml), nidogen-2 (4 g/ml), or perlecan (16 g/ml) diluted in PBS. Sections were rinsed in PBS and incubated (20 min) with 16 nm gold-coupled anti-rabbit IgG (1:200 in PBS). After rinsing with water and staining with uranyl acetate (15 min) and lead citrate (5 min), sections were examined with a Zeiss EM 109 microscope.
For double labeling, a hybridoma medium containing rat monoclonal antibody against endostatin with an enzymelinked immunoassay titer of 1:20,000 was used. The protocol was the same except that after treatment with the first and second antibody (see above), incubation was continued for 1 h with the monoclonal antibody (diluted 1:300, ϳ3 g/ml), followed by 8 nm gold-coupled anti-rat IgG (20 min). Nonspecific binding of the gold probes to anionic sites in tissues was examined by incubation with the colloidal gold alone prior to or after coupling to anti-IgG. All controls proved to be negative (not shown).
RESULTS
Immunofluorescence localization of endostatin in adult mouse tissues
Previous immunohistological data demonstrated endostatin in small blood vessels and in some basement membrane zones of many embryonic mouse tissues (19) . The data also indicated its presence in adult tissues, which were now analyzed more comprehensively by immunofluorescence (examples shown in Fig.  1 ) in order to identify appropriate targets for immunoelectron microscopy. Some of the strongest staining was observed in the aortic media ( Fig. 1A ) and included four or five lamellar structures reminiscent of the multiple elastic sheets. The adventitia showed only little staining, mainly in small vessels. A distinct staining of large vessel walls was a general observation and included portal veins and arteries as well as sinusoidal regions in the liver (Fig. 1B) , large arteries and veins in kidney, heart, and skeletal muscle, and, to a lesser extent, structures representing small vessels. Endostatin staining was also observed in the renal mesangium, Bowman's capsule, and along tubular basement membranes (Fig. 1C) . Staining of skin showed endostatin along the dermal-epidermal junction, around hair follicles and small vessels, and some additional extracellular deposits in the dermis (Fig. 1D ).
Immunogold staining shows endostatin association with elastic fibers of large vessels
Based on the immunofluorescence data, a greater number of blood vessels were examined in order to identify the ultrastructural localization of endostatin (Fig. 2) . In aorta, there was a strong staining of the elastic fiber underneath the endothelial cell layer ( Fig. 2A) and across all other elastic sheets within the media (Fig. 2B) . Extracellular labeling was found on top of amorphous elastic plaques as well as in close proximity to microfibrillar deposits. No or only little staining was observed in basement membranes adjacent to endothelial and smooth muscle cells and within the cells. A distinct but less intense endostatin staining was also found in elastic fibers of several large muscular arteries (Fig. 2C ) and in the extracellular matrix containing sparse elastic fibers of veins (Fig. 2D) and venules of variable size. A more quantitative analysis of identical areas of these vessels demonstrated 20 -25 gold particles on the elastic sheets and 3-5 on intracellular regions when compared to 1-3 gold particles in the negative controls, indicating that the differences are significant. Some but not all arterioles and capillaries examined also showed a weak labeling for endostatin. It was found in the vessel lumen. where it likely represents the circulating form of endostatin (19) , but was more prominent in microfibrillar regions underneath the vessel walls (Fig. 2E) . Again, no staining was found for basement membranes.
As expected, the same elastic fibers as shown in Fig. 2 could be strongly stained with antibodies to tropoelastin (data not shown). They were also labeled with antibodies against several extracellular matrix proteins known to be microfibrillar and/or vessel wall components (20 -22, 32, 33) in double staining experiments, as shown for the aortic media (Fig. 3) . Staining was observed for the elastic fiber components fibulin-2 (Fig. 3A) , fibulin-1 (Fig. 3B) , nidogen-2 (Fig. 3C) , and the heparan sulfate proteoglycan perlecan (Fig. 3D) , whereas versican and laminin-1 could not be detected. Double staining with a monoclonal antibody to endostatin showed a frequent colocalization within a distance of 10 -20 nm with fibulin-2 and nidogen-2 (Fig. 3A, C) . Such colocalizations were less obvious for fibulin-1 and negligible for perlecan (Fig. 3B, D) .
A few more tissue structures were studied by immunogold staining in order to get an overview of further ultrastructural associations of endostatin. In skin, there was a weak to moderate labeling of dermal collagen fibers and of the papillary dermis underneath the dermal-epidermal basement membrane (Fig. 2F) . The latter is known to contain many microfibrils composed of fibronectin, fibulin-2, and fibrillin (34) . Staining could not be detected in the dermal regions of sparse elastic fibers. A typical basement membrane staining for endostatin was found in the proximal tubules of kidney (Fig. 4A) , whereas glomerular basement membranes and the podocytes were only weakly labeled. In the liver, besides the large vessels, endostatin could be localized primarily to the rough endoplasmic reticulum and Golgi complex of hepatocytes (Fig. 4B) .
Solubilization and properties of endostatin from aorta and skin
The immunogold staining of aorta and skin suggested that they may differ in the content and molecular associations of endostatin. Both tissues were therefore subjected to three different extraction/digestion protocols: solubilization by EDTAcontaining neutral buffer, followed by detergents (procedure A), and two consecutive proteolytic digestions by either elastase, followed by collagenase (procedure B), or collagenase, followed by elastase (procedure C). All extracts were analyzed for their total protein and collagen contents and for the amount of solubilized endostatin antigen by radioimmunoassay ( Table 1) . For aorta, the most efficient extraction of endostatin was obtained using procedure A (ϳ80 g/g wet tissue), which corresponded to 0.5% of the total proteins solubilized. A comparable extraction of other mouse tissues (brain, kidney, liver, testis) by EDTA-containing buffer alone yielded soluble endostatin in the range 2-10 g/g wet tissue when compared to 38 g/g for aorta. The two proteolytic protocols solubilized much more total protein and collagen from aorta, but only 15-30% of the endostatin when compared to procedure A.
The skin contained less extractable endostatin (13 g/g wet tissue) than aorta when analyzed by procedure A, and again yielded lower amounts of endostatin by the proteolytic procedures B and C. A comparable extensive treatment of recombinant endostatin by either collagenase or elastase did not cause any change in electrophoretic mobility or any loss of antigenicity in the radioimmune inhibition assay. This confirmed previous observations of a high stability against neutral proteases (19) and demonstrated that the lower yields of endostatin in the proteolytic extracts are not due to degradation.
The nature of the endostatin antigen in the various extracts were analyzed by immunoblotting after electrophoretic separation (Fig. 5) . Most of the aorta extracts contained distinct components of 25 and 22 kDa, the latter being the size of recombinant endostatin. No larger material with the size of carboxylterminal domain NC1 (35-38 kDa) could be detected, although this has previously been shown to be prominent in muscle, testis, and liver extracts (19) . The 22 kDa form dominated in the skin extracts, some of which also contained a 38 and 60 kDa band that could represent NC1 and a larger partially degraded collagen XVIII fragment. A mixture of the EDTA and detergent extracts from aorta was also subjected to analytical heparin affinity chromatography, followed by radioimmunoassay quantitation of endostatin. This demonstrated efficient binding (Ͼ90%) and elution from the column at 0.34 M NaCl, similar to recombinant endostatin (19) , and indicated that the solubilized aorta endostatin is not complexed to a ligand that would interfere with heparin binding.
Binding of elastic fiber proteins to recombinant endostatin
Previous analysis by surface plasmon resonance assay demonstrated a distinct binding of endostatin to fibulins (19) . As a result of the colocalization data presented here, we examined these and other ligands in solid-phase assays (Fig. 6) . This demonstrated a relatively strong binding of soluble fibulin-2, nidogen-2, and fibulin-1 to immobilized endostatin (half-maximal at 1-10 nM) and a 10-to 100-fold weaker reaction with nidogen-1 and perlecan. A similar analysis with soluble tropoelastin showed a strong binding to albumin-coated control plastic wells (half-maximal at 2 nM) and only a slight increase in the presence of immobilized endostatin. No endostatin binding to immobilized tropoelastin was observed in solid-phase and surface plasmon Figure 5 . Immunoblot characterization of endostatin in various aorta (top) and skin (bottom) extracts. The extracts correspond to those described in Table 1 referred to as A1 to C2. They were obtained with EDTA-containing buffer (lanes A1), detergents (lanes A2), and digestion with elastase (lanes B1), followed by collagenase (lanes B2), or with collagenase (lanes C1) followed by elastase (lanes C2). Samples were run under reducing conditions and their positions marked in kilodaltons with calibrating proteins (left margins). The migration positions of the carboxyl-terminal domain NC1 and its endostatin (ES) part are indicated (right margins). The loading of individual lanes was variable and does not correspond to the amounts of endostatin shown in Table 1 . resonance assays, indicating a lack of any substantial affinity.
DISCUSSION
Endostatin derived from the carboxyl-terminal domain NC1 of collagen XVIII was shown by immunofluorescence to have a widespread localization in vessel walls and some basement membrane zones of adult mouse tissues. A similar localization was also found with antibodies against the amino-terminal domain NC11 of collagen XVIII (35-37), but it is unclear whether the two domains colocalize at the ultrastructural level. We used immunogold staining to clearly identify endostatin as an extracellular matrix component as well as finding it within some intracellular compartments. An unexpected finding was the strong association of endostatin with all elastic sheets in aorta. A distinct but less intense staining was observed in the elastic fibers of large arteries and veins. There was also a frequent colocalization with microfibrillar structures in the elastic lamellae of the aorta. Such structures also exist without elastin in the papillary dermis (34) and other extracellular locations. Intracellular endostatin was particularly prominent in hepatocytes, where it seems to be associated with the rough endoplasmic reticulum and Golgi complex and could thus contribute the plasma form of endostatin, as previously suggested (19) . This observation correlated well with a high expression of collagen XVIII in normal and fibrotic human liver (36) . Endostatin can, however, also be a basement membrane component, as shown for the proximal tubular epithelium of kidney. Thinner basement membranes in the close proximity to endothelial and smooth muscle cells of vessel walls could not be labeled for endostatin, but were negative for ubiquitous basement membrane proteins such as perlecan and nidogen-1 (data not shown). Therefore we cannot exclude that the fixation and surface immunogold staining protocol used here is not optimal for these basement membranes. Small capillaries that contained endostatin in the vessel lumen and more remote microfibrils also lacked vessel wall staining.
Recombinant endostatin produced and secreted by mammalian cells is a highly soluble and crystallizable protein (18, 19) . The localization of its tissue analogs to three different extracellular ultrastructures (amorphous elastic plaques, microfibrils, basement membranes) strongly suggests that endostatin is kept in place there by interactions with other structural extracellular ligands. Solid-phase binding assays identified fibulin-2, nidogen-2, and fibulin-1 as three potential ligands, whereas other interactions with nidogen-1 or perlecan may be too weak to be relevant. These observations correlated well with a distinct colocalization of endostatin with fibulin-2 and nidogen-2 in the elastic sheets of the aortic media. The double immunogold labels were often close enough (10 nm) to be consistent with molecular contacts. These postulated contacts will require additional biochemical characterization after chemical cross-linking of such complexes.
Elastic sheets and fibers are prominent in aorta and other large arteries but are also found in lung, skin, elastic cartilage, and some special tissues. They consist of a highly insoluble, covalently cross-linked network of elastin monomers (tropoelastin) that is frequently associated with fibrillin-containing microfibrils and some associated proteins (38, 39) . More recent additions to this complexity include fibulin-1 (40) and fibulin-2 (41) in dermal elastic fibers and, as shown here, in the elastic sheets of aorta. Fibulin-2 was also colocalized to microfibrils composed of either fibronectin or fibrillin (28, 34, 41) .
Besides endostatin, nidogen-2 and perlecan were also identified as novel components in the elastic structures of aorta by immunogold staining. Nidogen-2 is a recently discovered extracellular protein that has a length of ϳ50 nm, binds to collagen IV and perlecan, and is structurally and functionally related to the ubiquitous basement membrane protein nidogen-1 (22) . Nothing is known about its supramolecular organization and ultrastructural tissue localization. Recent data, however, indicate a strong affinity for tropoelastin (T. Sasaki, W. Göhr-ing, N. Miosge, J. Rosenbloom, R. Timpl, unpub- lished results), which could explain the nidogen-2 localization in aorta. The heparan sulfate proteoglycan perlecan is a well-characterized component of basement membranes and other interstitial spaces with many potential functions (33, 42) . It has not yet been identified in elastic structures, but our data agree with previous observations that they contain proteoglycans (39) . Perlecan may not be a relevant ligand for endostatin in the elastic parts of aorta because of its presumably low content, but it could serve this purpose in basement membranes.
Extraction and initial biochemical characterization of endostatin from various tissues (19) identified aorta as the richest source of the potential endothelial cell inhibitor known so far. Furthermore, the size of endostatin in aorta and skin extracts was in the range 22-25 kDa, which is similar to that of endostatin in human plasma but distinctly smaller than the major variants (35-38 kDa) found in several other tissues (19) . Full-length collagen XVIII was identified in tissues and cell cultures by antibodies against the amino-terminal domain NC11 as a 180 -200 kDa band (35, 37) , which we could not detect in aorta and skin by the endostatin antibodies. This indicates a complete proteolytic release of the carboxyl-terminal endostatin domain in both tissues, but we cannot entirely exclude the possibility that a heparan sulfate-substituted form of collagen XVIII (37, 43) may have escaped our detection. Based on previous data (19), we postulated that processing of collagen XVIII starts with the release of the carboxylterminal NC1 domain (38 kDa), as known for other procollagens, followed by a second proteolytic cleavage in a hinge region, which then releases endostatin with some variability in size (22) (23) (24) (25) . This process seems to be almost complete in aorta and skin and may not even require the initial proteolytic step.
In the tissue extraction of endostatin, a combination of neutral buffers with a chelating agent and detergents yielded the highest amounts from aorta and skin. This could reflect the small size of the endostatin antigens present there, but also implicates the involvement of divalent cations and hydrophobic interactions in the binding of endostatin to the extracellular matrix. In this context, it is of interest that human endostatin contains a single zinc atom (44) , as also found for mouse endostatin (T. Sasaki, E. Hohenester, R. Timpl, unpublished results). Whether the removal of zinc or of calcium from the potential fibulin and nidogen-2 ligands (20, 22, 28) is responsible for solubilization by EDTA remains to be analyzed. A more extensive tissue solubilization by a combination of elastase and collagenase treatments was less efficient for the extraction of endostatin, which was stable against both proteases. This agreed with our observations that endostatin and tropoelastin have no remarkable affinity for each other. The data also support our interpretation that most of the endostatin is already released from collagen XVIII, since no 38 kDa NC1 components could be detected by immunoblotting after collagenase treatment.
Relatively little is known about the biological role of endogenous endostatin except for indications that it could inhibit endothelial cell growth and interfere with tumor growth in experimental mouse models (7, 15) . Yet its abundance in many extracellular locations strongly suggests a role. We interpret our observation of a strong association with elastic structures of aorta as being mainly mediated by associated microfibrillar components containing fibulin-2 and/or nidogen-2. Other possible associations still remain to be identified. One major unresolved questions is whether domain NC1 itself has inhibitory activity or whether it requires further conversion to endostatin, which also decreases the potential for protein interactions (19) . Since the endostatin in aorta is near to the endothelial cell layer, one may speculate that this reservoir prevents deleterious angiogenesis from the luminal side that may be initiated by pathological triggers to the cells. The analysis of such possibilities and other parameters will become instrumental in understanding the endogenous control of angiogenesis inhibition.
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